KZIA
NASDAQKazia Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks72-100%
2026-04-262026-10-18
Mix4590d
- SEC Filings35(78%)
- Other6(13%)
- Offering3(7%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- PRKazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersClinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to KaziaSYDNEY, Sept. 22, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd., a biotechnology company specializing in central nervous system (CNS) diseases that has exclusively licensed paxalisib from Kazia for the development and commercialization of paxalisib as a potential treatment for mTORopathy-related epilepsies, has dosed the first patient in a Phase 1b/2a clinical trial eval
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- PRKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerMulticenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently existSYDNEY, Sept. 9, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combination with gemcitabine for patients ages 1 to 39 with recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT). AT/RT is wide
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- PRKazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to ImmunotherapyPaxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint InhibitionKazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in Immunotherapy-Resistant MSS/pMMR Colorectal CancerSYDNEY, Sept. 1, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical and translational d
- PRKazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast CancerPreclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-CareFirst Patient Expected By Year-End 2026 and Full Enrollment by End of 2027SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical data demonstrating the safety and anti-tumo
- PRKazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public OfferingCompany to host a corporate update call Tuesday, September 1st at 8:00am ETSYDNEY, Aug. 31, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its previously announced oversubscribed, tranched registered public offering (the "Offering") generating approximately $40 million in upfront gross proceeds. Both clinical milestone-linked warrant tranches were priced at premiums to the $15.50 offering price, with exercise prices of $17.825 per ADS, a 15% premium, tied to t
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
KZIA FAQ
6 questionsWhat does Kazia Therapeutics Limited do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Where does KZIA stock trade?
Kazia Therapeutics Limited (KZIA) is listed on NASDAQ.What sector and industry is KZIA in?
Kazia Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KZIA?
Kazia Therapeutics Limited has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $2900.00 price target on 2026-08-13.What companies are similar to KZIA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KZIA side-by-side with any of them on Quantisnow.How can I track KZIA on Quantisnow?
Quantisnow aggregates Kazia Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KZIA to receive live email and push alerts on every new disclosure.